Patients
Physicians
Sponsors
Oncologists
About Us
News
ENG
Last updated 35 days ago
Share
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
540 patients around the world
Available in
Spain, Argentina, United States
Janssen Research & Development, LLC
5
Research sites
540
Patients around the world
This study is for people with
Bladder Cancer
Non-muscle-invasive bladder cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Inclusion criteria
Exclusion criteria
Sites
Hospital Asociación de Beneficencia Hospital Sirio Libanes - CABA, Buenos Aires
Recruiting
View site
Campana 4658, CABA, Buenos Aires
https://hospitalsiriolibanes.org/
Centro Urológico Profesor Bengió - Córdoba
Recruiting
View site
Urquiza 358, 1er Piso.
www.grupobengio.com.ar/
Centro Médico Privado CEMAIC - Córdoba
Recruiting
View site
Monseñor Pablo Cabrera 2941, Córdoba
www.cemaic.com.ar
Hospital Privado de la Comunidad
Recruiting
View site
Córdoba 4545, Mar del Plata, Buenos Aires
Centro Gutman
Recruiting
View site
Av. Sta. Fe 3233, C1425BGH Cdad. Autónoma de Buenos Aires, Argentina
See details
Contact us
Contact us
Study
MoonRISe-1
Sponsor
Janssen Research & Development, LLC
Conditions
Non-muscle-invasive bladder cancer
Bladder Cancer
Requirements
From 18 Years
All Gender
Unique study ID
clinicaltrials.gov
NCT06319820
About us
Our mission
Our team
Partners
FAQs
Medical news
Latest news
Studies
Interviews
Testimonials
Products
UEPM Onco
UEPM Physicians
Links
Downloads
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent